# Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

> **NCT05889572** · PHASE1 · COMPLETED · sponsor: **MaaT Pharma** · enrollment: 15 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** MaaT033

## Key facts

- **NCT ID:** NCT05889572
- **Lead sponsor:** MaaT Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-08
- **Primary completion:** 2024-07-22
- **Final completion:** 2024-07-22
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889572, "Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05889572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*